Ajinomoto Co., Inc. has signed a licensing agreement with Astellas Pharma Inc. for the use of AJICAP—an antibody-drug conjugate (ADC) development and manufacturing technology—as part of its CDMO ...

Bayer’s Lynkuet, approved for treating moderate-to-severe vasomotor symptoms of menopause, targets two receptors key to ...

The field of oncology has been profoundly impacted by malignant solid tumours, representing a significant challenge in healthcare. While strides have been ...

The "Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The market's growth is primarily driven by the rising ...

Eli Lilly, Zyrtec and Astellas Pharma recently invested in celeb partnerships to raise awareness about conditions.

We demonstrate that patients with luminal B tumors derive clinically meaningful benefits … from the addition of apalutamide to secondary radiotherapy,” Dr Daniel Spratt said, adding that these ...

Final draft guidance on NHS use of the drug marks a "significant shift" from NICE's 2021 decision on the drug as a first-line ...

Unmanaged menopause symptoms can cost the economy $3.5 billion annually, prompting more companies to step up with supportive policies ...

RBC Capital Markets downgraded Bicycle Therapeutics ( BCYC) to sector perform from outperform, saying "pipeline programs are taking more time to reach inflection points." The bank cut its price target ...

A new study from Mayo Clinic underscores the widespread impact of menopause symptoms on midlife women — and raises concern that most are navigating this stage of life without medical care to help ...

To our knowledge, this is the greatest survival benefit, based upon hazard ratio, ever seen in a prostate cancer,” said study presenter Stephen J. Freedland, MD.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November ...